Subtype-Specific Antibiogram Display for Genomic Resistance Monitoring
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The rise of antimicrobial-resistant bacteria poses challenges in effectively managing antimicrobials and antimicrobial-resistant infections, particularly in clinical environments, where conventional methods rely heavily on doctor knowledge and experience rather than subtype-specific antimicrobial administration.
Innovation Solution
The use of next-generation sequencing technologies (NGS) and molecular epidemiology to generate subtype-specific antibiograms, which involve culturing pathogens, sequencing their genomes, comparing the data against databases, and presenting sensitivity/resistance information in graphical displays to guide appropriate antimicrobial treatment.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If conventional antibiogram methods are used, then the process is simple and quick, but the information is not subtype-specific and lacks precision in guiding treatment
Solution Approach 1:
The patent segments the antibiogram information by organizing sensitivity data according to specific bacterial subtypes rather than presenting aggregate data. This segmentation allows clinicians to access precise subtype-specific guidance while the system handles the complexity of genomic analysis in the background.
Solution Approach 2:
The patent introduces a computational intermediary system that performs genomic sequencing, subtype identification, and sensitivity analysis. This intermediary handles the complex genomic data processing, presenting simplified subtype-specific results to clinicians without requiring them to directly manage the complexity of genomic analysis.
2Measurement precision
If subtype-specific genomic analysis is implemented, then treatment precision is improved, but the time required for analysis increases
Solution Approach 1:
The patent implements preliminary action by pre-processing and pre-analyzing genomic data as it becomes available, rather than waiting for complete data sets. The system continuously updates subtype sensitivity information as new genomic sequences are analyzed, providing earlier preliminary results that can guide treatment decisions before complete analysis is finished.
Solution Approach 2:
The patent maintains continuity of useful action by implementing continuous genomic sequencing and analysis rather than batch processing. The system continuously updates antibiogram information as new data becomes available, ensuring that treatment guidance is continuously refined without requiring waiting for complete data sets, thus reducing overall time to actionable results.
3Reliability
If comprehensive genomic sequencing is performed, then resistance detection capability is enhanced, but the cost and complexity of the system increase
Solution Approach 1:
The patent extracts only the essential genomic information needed for subtype identification and sensitivity prediction, rather than analyzing entire genomes in detail. By focusing on specific genomic markers and comparative analysis of key regions, the system achieves reliable resistance detection while reducing overall system complexity and computational requirements.
Solution Approach 2:
The patent implements a universal database and analysis system that handles multiple bacterial species and subtypes through a single integrated platform. This multi-functional system can analyze different pathogens using the same genomic sequencing and comparison infrastructure, reducing per-application complexity while maintaining comprehensive detection capabilities across diverse organisms.
Data Source
AI summary
Methods and systems for monitoring and determining antimicrobial resistance and antimicrobial treatment using genomic subtype information. Various embodiments utilize molecular epidemiology and next-generation sequencing technologies (NGS) to monitor multi-drug resistant pathogens and provide early insight into emergent microbial threats.